Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057317 · ClinicalTrials.gov registry record · Phase 2
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00057317: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00057317 is a Phase 2 study that has completed, run by Hoffmann-La Roche. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057317, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.
Interventions
- DRUG Ro 205-2349
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-12 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
What the finished NCT00057317 record still lists
NCT00057317 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Ro 205-2349 is the first listed.
NCT00057317 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057317 about?
NCT00057317 is a clinical study titled "Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus". The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.
What is the current status of trial NCT00057317?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-12. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00057317?
The interventions under investigation include: Ro 205-2349 (DRUG).
Who is sponsoring clinical trial NCT00057317?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia